Newmont Reports Fourth Quarter and Full Year 2025 Results, Provides 2026 Guidance, and Announces Enhanced Capital Allocation Framework DENVER, February 19, 2026 – Newmont Corporation (NYSE: NEM, ASX: NEM, PNGX: NEM) (Newmont or the Company) today announced its fourth quarter and full year 2025 results, declared a fourth quarter dividend of $0.26 and provided guidance for the full year of 2026. 1 "2025 was a milestone year for Newmont, as we delivered on our full-year guidance, strengthened our financial pos ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Blue Acquisition Corp. Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-42699 (Exact name of registrant as specified in its charter) | Cayman Islands | 98-1855000 | | --- | --- | | ...

Exhibit 99.1 Spyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update On track for 6 proof-of-concept readouts in 2026 across the SKYLINE and SKYWAY Phase 2 trials Part A readouts from SKYLINE platform trial in ulcerative colitis ("UC") expected to begin in the second quarter, with enrollment continuing ahead of schedule Enrollment on track in Phase 2 SKYWAY basket trial evaluating TL1A inhibition in rheumatoid arthritis ("RA"), psoriatic arthritis ("PsA") ...

Exhibit 99.1 individuals in the U.S. Existing therapies for these diseases today generally offer incomplete efficacy, meaningful safety warnings, and inconvenient dosing profiles. Spyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update On track for 6 proof-of-concept readouts in 2026 across the SKYLINE and SKYWAY Phase 2 trials Part A readouts from SKYLINE platform trial in ulcerative colitis ("UC") expected to begin in the second quarter, with enrollment ...

Fiscal year 2025 subscription & support revenue increased by 22% Total revenue was $885 million, up 20% year-over-year GAAP operating margin was (4.8)%, non-GAAP operating margin was 9.9% Operating cash flow margin was 15.8%, free cash flow margin was 15.6% Repurchased $72 million worth of Class A common stock in 2025 under the 2024 share repurchase plan Announced increase to 2024 share repurchase plan by additional $250 million Workiva Announces Fourth Quarter and Full Year 2025 Financial Results Fiscal fo ...

Exhibit 99.1 Texas Roadhouse, Inc. Announces Fourth Quarter 2025 Results Increases Quarterly Dividend to $0.75 per Share LOUISVILLE, KY. (February 19, 2026) – Texas Roadhouse, Inc. (NasdaqGS: TXRH), today announced financial results for the fourth quarter and fiscal year ended December 30, 2025. Financial Results Financial results for the fourth quarter and fiscal year ended December 30, 2025 and December 31, 2024 were as follows: | | Fourth Quarter Ended | | | Fiscal Year Ended | | | | --- | --- | --- | -- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from_______________________to_______________________ Commission File No. 1-32525 AMERIPRISE FINANCIAL, INC. (Exact name of registrant as specified in its charter) Delaware 13-31806 ...

Exhibit 99.1 Inseego Reports Fourth Quarter and Full-Year 2025 Financial Results Q4 2025 revenue of $48.4 million, third consecutive quarter of sequential growth Q4 2025 Adjusted EBITDA* of $6.0 million and 12.4% margin and GAAP Net Income of $0.5 million Eliminated all outstanding Preferred Stock at 38% Discount SAN DIEGO—February 19, 2026—Inseego Corp. (Nasdaq: INSG) (the "Company"), a global leader in 5G mobile broadband and 5G fixed wireless access (FWA) solutions, today reported its results for the fou ...

Financial Performance and Risks - The company has incurred losses each year since its inception in October 2007, with an accumulated deficit of $946.9 million as of December 31, 2025[126]. - The company's ability to achieve cash flow positivity is heavily dependent on the successful commercialization of IBSRELA and XPHOZAH, as well as potential pipeline expansions[128]. - Future funding requirements will be influenced by the ability to generate revenue from IBSRELA and XPHOZAH, as well as ongoing clinical trials and development costs[133]. - The overall commercial success of IBSRELA and XPHOZAH will depend on market acceptance, reimbursement levels, and competition from alternative treatments[137]. - The company faces risks related to maintaining adequate third-party reimbursement for both IBSRELA and XPHOZAH, which could affect revenue generation[141]. - The effectiveness of IBSRELA and XPHOZAH as treatments will be critical for securing market share and achieving financial goals[140]. - The company may require additional financing to support the growth of IBSRELA and XPHOZAH and to build its product pipeline[133]. - The company faces substantial liabilities from potential product liability lawsuits related to IBSRELA and XPHOZAH, which could limit commercialization efforts[186]. - The company maintains product liability insurance, but claims may exceed coverage limits, leading to significant financial burdens[187]. Commercialization and Market Dynamics - The commercialization of IBSRELA began in March 2022, and XPHOZAH was launched in November 2023, targeting specific patient populations[126]. - The elimination of Medicare Part D coverage for XPHOZAH on January 1, 2025, is expected to negatively impact revenue growth and market acceptance[130]. - The lack of Medicare Part D coverage for XPHOZAH is anticipated to lead to a materially lower pace of revenue growth compared to prior expectations[145]. - The commercial success of XPHOZAH may be limited by undesirable side effects or other properties that could affect market acceptance[146]. - Third-party payor coverage and reimbursement for IBSRELA and XPHOZAH are uncertain, which could limit marketing capabilities and revenue generation[150]. - The pricing, coverage, and reimbursement for IBSRELA and XPHOZAH must be adequate to support a commercial infrastructure, as inadequate reimbursement could hinder successful commercialization[150]. - International operations face extensive governmental price controls, which may pressure pricing and usage of IBSRELA and XPHOZAH, potentially leading to insufficient revenue generation[152]. - Increasing efforts by payors to cap healthcare costs may limit coverage and reimbursement levels for newly approved products, impacting revenue potential[153]. - The company relies on third-party manufacturers for IBSRELA and XPHOZAH, and any disruptions in their ability to meet regulatory requirements could materially harm commercialization efforts[154]. Drug Development and Regulatory Challenges - The drug development process is long and uncertain, with significant risks involved in obtaining regulatory approval for product candidates[160]. - Ongoing development activities may face delays due to healthcare staffing shortages and increased competition for clinical trial sites, potentially impacting timelines and budgets[164]. - The drug development process is lengthy, with only a small percentage of drugs successfully completing FDA approval, which could hinder commercialization efforts[167]. - The company relies on single-source manufacturers for critical components, exposing it to supply chain risks, including delivery failures and drug shortages[169]. - The FDA's ability to review and process regulatory submissions may be hindered by funding shortages or global health concerns, potentially delaying drug approvals[231]. - Regulatory authorities can impose sanctions for non-compliance, including withdrawal of approvals or suspension of production, which could materially harm the company's business[236]. - Delays or failures in obtaining regulatory approvals could negatively impact the company's ability to commercialize products, affecting financial results[245]. Competition and Market Position - Competition for IBSRELA includes established products like Linzess and Amitiza, as well as generic alternatives, which may impact market share[176]. - XPHOZAH faces competition from various phosphate binders, including generics, which could affect its market positioning[177]. - The biotechnology industry is highly competitive, with larger companies having more resources, which may hinder the company's ability to compete effectively[180]. - The company may engage in strategic transactions, such as acquisitions or partnerships, which could increase expenses and distract management from core operations[182]. Compliance and Legal Risks - The company must ensure compliance with Good Clinical Practices (GCPs) and Good Laboratory Practices (GLPs) in clinical trials, as non-compliance could lead to unreliable data and additional regulatory hurdles[207]. - The company is subject to evolving data protection regulations, including the GDPR, which imposes fines of up to €20 million or 4% of annual global revenue for non-compliance[194]. - Non-compliance with data protection laws could result in negative publicity, government investigations, and financial penalties, adversely affecting operations and financial performance[190]. - The company is subject to extensive regulations regarding the promotion of its products, and failure to comply could lead to substantial fines or sanctions[239]. - Investigations into the promotion of products for unapproved uses could result in civil or criminal penalties, adversely affecting the company's financial prospects[240]. - The company must report adverse medical events related to its products, and failure to do so could lead to significant sanctions[242]. Intellectual Property and Trade Secrets - The company relies on a combination of legal protections, including patents and trade secrets, to safeguard its intellectual property, but these measures provide limited protection against competitors[260]. - There is a risk that the company may fail to obtain or enforce necessary intellectual property rights, which could negatively impact its competitive position and lead to significant expenses[261]. - The company has a portfolio of issued and pending patent applications, but there is a possibility of failing to identify patentable aspects of inventions, which could hinder future patent protection[262]. - The enforceability of patents in the biotechnology and pharmaceutical fields is uncertain, and challenges to patent validity could adversely affect the company's ability to compete effectively[274]. - The company may face third-party claims alleging infringement of intellectual property rights, which could result in costly litigation and impact product development[269]. Financial Position and Market Conditions - As of December 31, 2025, the company had cash, cash equivalents, and short-term investments totaling $264.7 million, including high-quality fixed income instruments[412]. - The principal outstanding under the 2022 Loan Agreement is $200.0 million, subject to a variable interest rate that could increase interest expenses by approximately $1.8 million with a 100 basis points rise in the one-month CME Term SOFR[413]. - The company maintains its excess cash in money market funds and short-term debt securities to minimize interest rate risk, believing that a 10% movement in market interest rates would not significantly impact the portfolio's total value[412]. - The company is exposed to foreign currency risk due to transactions in currencies other than the U.S. dollar, primarily Swiss francs, Japanese yen, and the Euro[414]. - The company does not intend to pay dividends on its common stock for the foreseeable future, which means stockholders' returns will depend on the appreciation of the stock price[313].

Financial Performance and Risks - The company's backlog as of December 31, 2025, was $11.94 billion, indicating potential revenue yet to be recognized[74] - Approximately 5.0% of the company's revenue for the year ended December 31, 2025, was attributable to projects in the government sector, highlighting dependency on government spending[72] - One customer represented approximately 12.8% of the company's consolidated revenue in 2025, indicating a risk of revenue concentration[75] - Rising inflation has increased costs for labor, materials, and services, which may adversely affect profitability and cash flows[76] - The company is exposed to cost overruns in contracts, which could lead to reduced profits or losses if costs exceed estimates[73] - Delays and defaults in customer payments could materially affect the company's financial condition and cash flows[90] - The company operates in a highly competitive market, which may pressure profit margins and market share[77] - The company has experienced significant fluctuations in its common stock price, which may continue and could result in losses for shareholders[131] - The company’s financial results are subject to review by taxing authorities, and outcomes differing from recorded liabilities could adversely affect financial condition[128] - Warranty claims, while historically not material, could require the company to incur costs for repairs or replacements, adversely affecting financial results[117] - The company faces potential legal claims that could reduce profitability and liquidity, impacting financial condition and cash flows[116] - Tax matters, including changes in corporate tax laws, could materially impact the company's financial results and condition[127] Operational Challenges - The company may face challenges in integrating future acquisitions, which could impact financial performance and operational efficiency[78] - Labor shortages and increased labor costs from third parties could adversely impact the company's results of operations[83] - The company faces challenges in attracting and retaining qualified personnel, which could increase labor costs and affect operational efficiency[97] - Growth may impose additional responsibilities on senior management, and failure to manage growth effectively could hinder operational expansion[98] - The decentralized decision-making structure may slow the company's response to operational issues and compliance risks[99][100] - Ineffective management of backlog and operational costs could strain resources and hinder revenue growth[101] - The company’s workforce utilization directly impacts profitability; underutilization could lead to lower gross margins[114] Regulatory and Compliance Risks - The company is subject to various environmental regulations, including the federal Clean Air Act, which could impose significant additional costs and reduce profits[122] - The company may face challenges in obtaining necessary insurance coverage, which could increase overall risk exposure and limit project opportunities[110][112] - Non-compliance with credit agreement covenants could lead to default, impacting the company's ability to operate and service debt obligations[113] - The company has 190 locations across 27 states, exposing it to various state and local regulations, which could increase costs and negatively impact financial condition[120] - The company may face increased regulatory scrutiny and compliance costs related to data privacy and cybersecurity threats[109] Market and Economic Conditions - Political and economic uncertainties, including inflation and supply chain disruptions, may constrain customer spending and impact the company's financial condition[95] - Changes in U.S. foreign trade policies could lead to additional trade barriers, negatively impacting the company's ability to purchase materials and supplies[126] - The company is susceptible to adverse weather conditions, which may lead to service curtailment, operational suspension, and potential liability for liquidated damages[92] - Future climate change poses physical and financial risks, including increased extreme weather events that could delay or cancel projects[93] - Ongoing political and economic uncertainties, including inflation and supply chain disruptions, may hinder the company's ability to forecast and plan business activities[95] Internal Controls and Reporting - The company plans to maintain and strengthen internal controls to enhance the effectiveness of financial reporting[141] - The company’s internal control over financial reporting is assessed annually, and findings of inadequacy could reduce investor confidence in financial information[139] - Changes in accounting rules could adversely affect reported financial results and require significant changes to systems and processes[142] - Any deficiencies in internal control could lead to a material weakness, potentially resulting in misstatements of financial statements and loss of investor confidence[140] Cybersecurity and IT Risks - Cybersecurity risks threaten the integrity of IT systems, potentially leading to financial losses and operational disruptions[102][103] - IT system failures and cybersecurity breaches could disrupt operations and lead to significant financial losses[102][107]